32454-26-5

Basic information

• Product Name: methyl α-(3-methylphenyl)isobutyrate
• Synonyms: methyl α-(3-methylphenyl)isobutyrate
• CAS NO: 32454-26-5
• Molecular Weight: 192.258
• Mol File: 32454-26-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: methyl α-(3-methylphenyl)isobutyrate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl α-(3-methylphenyl)isobutyrate(32454-26-5)
• EPA Substance Registry System: methyl α-(3-methylphenyl)isobutyrate(32454-26-5)

Safety Data

• Hazardous Substances Data: 32454-26-5(Hazardous Substances Data)

Upstream product

• 53088-69-0 methyl 3-methylphenylacetate 
• 74-88-4 methyl iodide 
• 6651-34-9 2-methyl-1-(trimethylsilyloxy)-1-propene 
• 591-17-3 meta-bromotoluene 
• 547-63-7 Methyl isobutyrate 

Downstream Products

• 32454-27-6 2-methyl-2-(m-tolyl)propan-1-ol 
• 1571031-99-6 methyl 2-(3-(bromomethyl)phenyl)-2-methylpropanoate 
• 32454-13-0 2-methyl-2-(m-tolyl)propanal 
• 1026841-30-4 [2-(4-fluoro-phenyl)-1-({2-methyl-1-[5-(1-methyl-1-m-tolyl-ethyl)-[1,3,4]oxadiazole-2-carbonyl]-propylcarbamoyl}-methyl)-6-oxo-1,6-dihydro-pyrimidin-5-yl]-carbamic acid benzyl ester 
• 1025995-54-3 {2-(4-fluoro-phenyl)-1-[(1-{hydroxy-[5-(1-methyl-1-m-tolyl-ethyl)-[1,3,4]oxadiazol-2-yl]-methyl}-2-methyl-propylcarbamoyl)-methyl]-6-oxo-1,6-dihydro-pyrimidin-5-yl}-carbamic acid benzyl ester 
• 1027494-17-2 (1-{hydroxy-[5-(1-methyl-1-m-tolyl-ethyl)-[1,3,4]oxadiazol-2-yl]-methyl}-2-methyl-propyl)-carbamic acid tert-butyl ester 
• 1026444-42-7 2-(1-methyl-1-m-tolyl-ethyl)-[1,3,4]oxadiazole 
• 1027543-64-1 2-methyl-2-m-tolyl-propionic acid hydrazide 

Relevant articles and documents

Small Molecule Analogs of the Nemo Binding Peptide

The invention is directed to a method of inhibiting, within a living cell, the interaction between NF-κB essential modulator (“NEMO”) with IκB kinase-β (IKK-β) at the NEMO binding domain (NBD), comprising exposing the cell to an effective amount or concentration of a compound of the invention, a NEMO-binding domain analog (NBDA). The invention is further directed to a method of treating a condition in a patient, wherein inhibiting the interaction between NF-κB essential modulator (“NEMO”) with IκB kinase-β (IKK-β) at the NEMO binding domain (NBD) is medically indicated, comprising administering to the patient an effective dose of a compound of the invention. Conditions that can be treated by a method of the invention includes muscular dystrophy, asthma, inflammatory bowel disease, multiple sclerosis, Parkinson's Disease, arthritis, diabetes, graft versus host disease, accelerated aging, heart ischemia, cancer, UV-induced skin damage, or an age-related pathology.

HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE

The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.

Development of orally active nonpeptidic inhibitors of human neutrophil elastase

5-Amino-2-phenylpyrimidin-6-ones, some of their desamino derivatives, and miscellaneous derivatives were synthesized and biologically evaluated on both in vitro activity and oral activity in an acute hemorrhagic assay. These compounds contained an α-keto-1,3,4-oxadiazole moiety to bind covalently to the Ser-195 hydroxy group of human neutrophil elastase (HNE). Among those tested, compounds 11a-c,e,i-l(F), 11d,e,k(H), 21d,e,k(F), and 21d,e(H) showed a good oral profile. RS-Mixture 3(H) was selected for clinical evaluation based on its oral potency, duration of action, enzyme selectivity, safety profile, and ease of synthesis. Structure -activity relationships (SARs) are discussed.